Each tablet contains Glimepiride 4 mg and Metformin Hydrochloride 1000 mg (Sustained Release).

Diapride M4 Forte Tablets combine Glimepiride and Metformin Sustained Release to provide dual-mechanism glycemic control for adults with type 2 diabetes mellitus. Glimepiride stimulates insulin secretion from functioning pancreatic β-cells, while Metformin decreases hepatic glucose production, reduces intestinal glucose absorption, and enhances peripheral insulin sensitivity. This complementary combination effectively controls fasting and postprandial blood glucose levels and is suitable for patients requiring intensified oral antidiabetic therapy when lifestyle modification and monotherapy are insufficient.

Diapride M4 Forte Tablets are indicated for the treatment of adults with type 2 diabetes mellitus when diet, exercise, and single-agent therapy do not provide adequate glycemic control.

Glimepiride lowers blood glucose primarily by stimulating insulin release from functioning pancreatic β-cells. In addition to its pancreatic action, it exerts extra-pancreatic effects that improve insulin sensitivity. Metformin is an antihyperglycemic agent that decreases hepatic glucose production, reduces intestinal glucose absorption, and improves peripheral glucose uptake and utilization. The sustained-release formulation of Metformin provides prolonged glycemic control, while the combination with Glimepiride offers complementary mechanisms for effective management of type 2 diabetes mellitus.

The recommended dosage is one tablet taken orally once daily with breakfast or the first main meal of the day, or as directed by the treating physician. Dosage should be individualized according to the patient's glycemic response and clinical requirements.

Diapride M4 Forte Tablets are contraindicated in patients with known hypersensitivity to Glimepiride, Metformin, or any component of the formulation. The medication is also contraindicated in patients with acute or chronic metabolic acidosis, including diabetic ketoacidosis, with or without coma.